Polo-like kinase 1 and sphingosine-1-phosphate circuitry enhances TSC-mutant cell survival
Polo 样激酶 1 和 1-磷酸鞘氨醇电路可增强 TSC 突变细胞的存活
基本信息
- 批准号:10915745
- 负责人:
- 金额:$ 10万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-20 至 2024-09-19
- 项目状态:已结题
- 来源:
- 关键词:AngiomyolipomaApoptosisAttenuatedBackBiologicalBiological ProcessCRISPR/Cas technologyCell DeathCell ProliferationCell SurvivalCell physiologyCellsCeramidesClinical Trials DesignCystCytokine-Inducible KinaseCytostaticsDataEnzymesEventExhibitsFDA approvedFutureGenesGoalsGrowthGuide RNAHemorrhageImmunoblot AnalysisIn VitroInduced MutationInduction of ApoptosisKidney DiseasesKidney FailureKidney NeoplasmsKnock-outLesionLuciferasesMediatingMediatorMedicalMetabolismMitosisMitoticMolecularMorbidity - disease rateMusMutationNecrosisNull LymphocytesPIK3CG genePLK1 genePathway interactionsPatientsPharmaceutical PreparationsPhenotypePhosphorylationPlasmidsPlayPositioning AttributePredispositionProductionProliferatingPublishingRare DiseasesRegulatory PathwayRemission Induction TherapyRenal AngiomyolipomaRenal Cell CarcinomaReverse Transcriptase Polymerase Chain ReactionRiskRoleSPHK1 enzymeSignal TransductionSourceSphingolipidsSphingosine-1-Phosphate ReceptorTSC1 geneTSC1/2 geneTSC2 geneTechnologyTestingTuberous SclerosisValidationWithholding TreatmentWorkXenograft procedurecell growthdesaturasedihydroceramide desaturasegalactosylgalactosylglucosylceramidaseimprovedin vivoinhibitorkidney dysfunctionknock-downknockout geneloss of function mutationlung colonizationmTOR Signaling Pathwaymortalitymutantneoplastic cellpreventrestorationside effectsphingosine 1-phosphatetargeted agenttreatment strategytumortumor growth
项目摘要
Renal disease (cysts, angiomyolipomas (AML), renal dysfunction, and renal cell carcinoma) is a major cause of morbidity and mortality in Tuberous Sclerosis Complex (TSC), a rare disease caused by loss-of-function mutations in TSC1 or TSC2 gene that lead to aberrant activation of the PI3K/mTOR signaling pathway. Treatment with mTORC1 inhibitors (mTORi) partially decreases the volume of angiomyolipomas in TSC, but tumors regrow when treatment is discontinued. Because of these primarily cytostatic effects of mTORi, life-long therapy is required with increased risk for side effects. Sphingolipids play key roles as mediators of cellular functions, including proliferation, necrosis, and apoptosis. Relevant to our proposal, the two central bioactive sphingolipids, ceramide and sphingosine-1-phosphate (S1P), exhibit opposing roles in regulating cell death and survival. Sphingolipid signaling is associated with mitotic events and activation of polo-like kinase 1 (PLK1). PLK1 interacts with and phosphorylates TSC1 to regulate mTORC1. TSC-deficient cells have aberrant mitosis, increased PLK1 levels and are sensitive to PLK1 inhibitors. In preliminary data we demonstrate that three key enzymes responsible for the synthesis and action of the primary bioactive sphingolipids, ceramide, and sphingosine-1-phosphate (S1P), namely dihydroceramide desaturase 1 (DEGS1), acid ceramidase (ASAH1), and sphingosine kinase 1 (SPHK1), are markedly activated in TSC2-null AML-derived cells. Our central hypothesis is that TSC mutations, by increasing the expression of PLK1 and S1P receptor 1 and 3 (S1PR1 and S1PR3), regulate the production of bioactive sphingolipids that facilitate cell survival. Successful completion of the proposed Aim 1 studies will establish stable AML-derived cells with depleted PLK1, S1PR1, and S1PR3 genes and non-targeting control using CRISPR/Cas9 gene editing technology. Successful completion of the proposed Aim 2 studies will demonstrate the biological consequences of CRISPR/Cas9 knock-out PLK1, S1PR1, and S1PR3 genes on sphingolipid actions and cell survival in vitro. The significance of this project is that it will successfully develop critical AML-derived PLK1, S1PR1, or S1PR3 gene knock-out cells with validated biological functions for future studies to investigate PLK1 and sphingolipid circuitry in TSC renal angiomyolipomas. These future studies are expected to have a positive impact because a mechanism-based understanding of sphingolipid metabolism and actions will lead to improved strategies for the treatment of TSC and other renal diseases.
肾脏疾病(囊肿、血管平滑肌脂肪瘤(AML)、肾功能障碍和肾细胞癌)是结节性硬化症(TSC)发病和死亡的主要原因,TSC是一种罕见的疾病,由TSC1或TSC2基因的功能丧失突变引起PI3K/mTOR信号通路的异常激活。使用mTORC1抑制剂(mTORi)治疗可部分减少TSC中血管平滑肌脂肪瘤的体积,但当停止治疗时,肿瘤会重新生长。由于这些主要的细胞抑制作用,mTORi需要终身治疗,副作用的风险增加。鞘脂作为细胞功能的介质发挥关键作用,包括增殖、坏死和凋亡。与我们的建议相关,神经酰胺和鞘氨醇-1-磷酸(S1P)这两种中枢生物活性鞘脂在调节细胞死亡和存活方面表现出相反的作用。鞘脂信号传导与有丝分裂事件和polo样激酶1 (PLK1)的激活有关。PLK1与TSC1相互作用并磷酸化以调节mTORC1。tsc缺陷细胞有丝分裂异常,PLK1水平升高,对PLK1抑制剂敏感。在初步数据中,我们证明了三个关键酶,即二氢神经酰胺去饱和酶1 (DEGS1),酸性神经酰胺酶(ASAH1)和鞘氨醇激酶1 (SPHK1),在tsc2缺失的aml衍生细胞中显着激活。我们的中心假设是TSC突变通过增加PLK1和S1P受体1和3 (S1PR1和S1PR3)的表达,调节促进细胞存活的生物活性鞘脂的产生。成功完成拟议的Aim 1研究将使用CRISPR/Cas9基因编辑技术建立稳定的aml来源细胞,其缺失PLK1, S1PR1和S1PR3基因和非靶向控制。成功完成拟议的Aim 2研究将证明CRISPR/Cas9敲除PLK1、S1PR1和S1PR3基因对鞘脂作用和体外细胞存活的生物学影响。该项目的意义在于,它将成功开发出具有生物学功能的aml来源的关键PLK1、S1PR1或S1PR3基因敲除细胞,为未来研究TSC肾血管平滑肌脂肪瘤中的PLK1和鞘脂通路提供基础。这些未来的研究有望产生积极的影响,因为基于机制的鞘脂代谢和作用的理解将导致改善TSC和其他肾脏疾病的治疗策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jane Yu其他文献
Jane Yu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jane Yu', 18)}}的其他基金
Targeting prostaglandin biosynthesis and action in lymphangioleiomyomatosis
靶向前列腺素生物合成及其在淋巴管平滑肌瘤病中的作用
- 批准号:
9367516 - 财政年份:2017
- 资助金额:
$ 10万 - 项目类别:
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders
前列腺素生物合成:TSC 疾病的新治疗靶点
- 批准号:
8760750 - 财政年份:2014
- 资助金额:
$ 10万 - 项目类别:
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders
前列腺素生物合成:TSC 疾病的新治疗靶点
- 批准号:
8917941 - 财政年份:2014
- 资助金额:
$ 10万 - 项目类别:
Prostaglandin biosynthesis: a novel therapeutic target in TSC disorders
前列腺素生物合成:TSC 疾病的新治疗靶点
- 批准号:
9145688 - 财政年份:2014
- 资助金额:
$ 10万 - 项目类别:
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
- 批准号:
9171443 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
- 批准号:
8646964 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
- 批准号:
8123223 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
- 批准号:
8269026 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
- 批准号:
7985437 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
Targeting the Estrogen Pathway for the Prevention and Treatment of LAM
靶向雌激素途径预防和治疗 LAM
- 批准号:
8474830 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 10万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 10万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 10万 - 项目类别:
Discovery Grants Program - Individual